Reserve Study Sample Clauses

Reserve Study. Borrower agrees to complete a reserve study in respect of the Shore Crest Phase II Association and the Shore Crest Phase II Resort and to submit the same to Lender on or prior to the second anniversary of the date hereof. Such reserve study shall be satisfactory to Lender in its reasonable discretion.
Sample 1
Reserve Study. Commencing on the fifth (5th) anniversary date of the CO Date, and every five (5) years thereafter during the Term of this Contract, Concessionaire shall cause to have a reserve study prepared within one hundred twenty (120) days from such anniversary date, by a company, subject to County’s approval (which shall not be unreasonably withheld), who has special expertise in preparing capital improvement reserve studies for similar projects (the “Reserve Study”). The Reserve Study shall contain, at a minimum, the following:
Sample 1
Reserve Study. After the Condominium first (1st) full Fiscal Year of operations, but in no event later than the expiration of the third (3rd) full Fiscal Year of operations and thereafter from time to time but no more frequently than every three (3) years unless requested by the Unit Owners Assembly or required by the Condominium Instruments or Applicable Laws, Manager shall commission a third-party study to evaluate the Reserve Account Obligations and the adequacy of the contributions to the Reserve Account to meet such Reserve Account Obligations (the “Reserve Study”). The cost and expense of the Reserve Study shall be a Common Expense.
Sample 1

Related to Reserve Study

  • Board of Governors (hereinafter called the Board) is the body referred to by that name in the Carleton University Act.

  • Federal Reserve Regulations (a) None of Holdings, the Borrower or any of the Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of buying or carrying Margin Stock.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.